Zydus Lifesciences will roll out generic semaglutide injections in India post-patent expiry, using a reusable single-pen ...

Ahmedabad: Zydus Lifesciences Limited said it plans to launch semaglutide injection in India under the brand names Semaglyn, Mashema and Alterme after.

This injection reduces the production of angiotensin, a hormone that increases blood pressure, in the body.

Zydus Lifesciences will launch generic versions of semaglutide injections for obesity and diabetes in India after patent expiry of the Ozempic active ingredient in late March, it said on Wednesday.

One of the standout features of Zydus' semaglutide offering is its unique, indigenously developed drug delivery system ...

Patent protection for semaglutide, the active ingredient in Danish drugmaker Novo Nordisk's diabetes drug Ozempic and ...

Zydus to launch Semaglutide Injection in India, featuring a unique reusable pen for improved diabetes and obesity management.